18 related articles for article (PubMed ID: 6642414)
1. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023).
Harris M; Schiff DM; Saia K; Muftu S; Standish KR; Wachman EM
Breastfeed Med; 2023 Oct; 18(10):715-733. PubMed ID: 37856658
[No Abstract] [Full Text] [Related]
2. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.
Müller EE; Locatelli V; Cella S; Peñalva A; Novelli A; Cocchi D
Drugs; 1983 Apr; 25(4):399-432. PubMed ID: 6133737
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced changes in prolactin secretion. Clinical implications.
Hell K; Wernze H
Med Toxicol Adverse Drug Exp; 1988; 3(6):463-98. PubMed ID: 3063922
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia: neuroendocrine and diagnostic aspects.
Camanni F; Ciccarelli E; Ghigo E; Müller EE
J Endocrinol Invest; 1989 Oct; 12(9):653-68. PubMed ID: 2685096
[No Abstract] [Full Text] [Related]
5. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
[TBL] [Abstract][Full Text] [Related]
6. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects.
Camanni F; Genazzani AR; Massara F; La Rosa R; Cocchi D; Müller EE
Neuroendocrinology; 1980; 30(1):2-6. PubMed ID: 7354887
[TBL] [Abstract][Full Text] [Related]
7. Nomifensine: diagnostic test in hyperprolactinemic states.
Müller EE; Genazzani AR; Murru S
J Clin Endocrinol Metab; 1978 Dec; 47(6):1352-7. PubMed ID: 263356
[TBL] [Abstract][Full Text] [Related]
8. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
9. Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia.
Genazzani AR; Cavagnini F; Picotti GB; Ghigo E; De Leo V; Galva MD; Maraschini C; Muller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1159-63. PubMed ID: 6630411
[TBL] [Abstract][Full Text] [Related]
10. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia.
DeLeo V; Cella SG; Camanni F; Genazzani AR; Müller EE
Horm Metab Res; 1983 Sep; 15(9):439-43. PubMed ID: 6642414
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
